Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Operations: 2019-2025

Historic Cash from Operations for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$81.5 million.

  • Beam Therapeutics' Cash from Operations rose 7.54% to -$81.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$338.2 million, marking a year-over-year decrease of 149.01%. This contributed to the annual value of -$347.2 million for FY2024, which is 132.75% down from last year.
  • Beam Therapeutics' Cash from Operations amounted to -$81.5 million in Q3 2025, which was down 6.58% from -$76.5 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Cash from Operations peaked at $218.5 million during Q1 2022, and registered a low of -$109.8 million during Q1 2023.
  • In the last 3 years, Beam Therapeutics' Cash from Operations had a median value of -$84.7 million in 2023 and averaged -$68.9 million.
  • Within the past 5 years, the most significant YoY rise in Beam Therapeutics' Cash from Operations was 666.36% (2022), while the steepest drop was 3,880.93% (2022).
  • Beam Therapeutics' Cash from Operations (Quarterly) stood at $1.8 million in 2021, then tumbled by 3,880.93% to -$69.2 million in 2022, then spiked by 295.22% to $135.1 million in 2023, then plummeted by 156.54% to -$76.4 million in 2024, then rose by 7.54% to -$81.5 million in 2025.
  • Its Cash from Operations was -$81.5 million in Q3 2025, compared to -$76.5 million in Q2 2025 and -$103.9 million in Q1 2025.